Meta-analysis of side effects of statins shows need for trial transparency. by Goldacre, Ben
Goldacre, B (2014) Meta-analysis of side effects of statins shows need
for trial transparency. BMJ (Clinical research ed), 348. g2940. ISSN
0959-8138 DOI: 10.1136/bmj.g2940
Downloaded from: http://researchonline.lshtm.ac.uk/1678259/
DOI: 10.1136/bmj.g2940
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial
http://creativecommons.org/licenses/by-nc/2.5/
STATIN SIDE EFFECTS STUDY
Meta-analysis of side effects of statins shows need for
trial transparency
Ben Goldacre Wellcome research fellow in epidemiology
London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
As Wise reported,1 our meta-analysis looked at side effects in
randomised trials of statins and found that many, such as muscle
aches, were reported to an equal degree by participants taking
a placebo. Those side effects may therefore be partly
non-pharmacological, and due to negative expectations, or the
“nocebo” effect, as has been shown in research on other drugs.2-4
For treatments where sufficiently large numbers of participants
have been randomised, trials can potentially give more accurate
information than observational studies on side effects.
Unfortunately, although our methods were sound, the reliability
of our findings is probably undermined by the poor reporting
of side effects in clinical trials reports in academic journals, as
discussed in our paper. Of particular interest is a study by
IQWiG, the German government’s cost effectiveness agency,
which was published after our study was conducted. It found
on average that complete information was given for 87% of
adverse event outcomes in the clinical study report (the standard
lengthy regulatory document for industry trials), but for only
26% of adverse event outcomes in the academic journal
publication.5
This is one more reason why the AllTrials.net campaign asks
for all trials to be registered, with their full methods and results
reported, including the clinical study report, if one has been
created.We cannot help patients make informed decisions about
the risks and benefits of treatments until this information is
routinely shared with doctors, researchers, and patients.6 7
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